Vor Bio is the latest cell therapy company to reach the end of the road. | Vor Bio is the latest cell therapy company to ...

NKGen Biotech CEO Paul Song, M.D., is putting his money where his mouth is, investing $2.65 million of his own cash to help ...

The FDA has appointed its first chief artificial intelligence officer, with an eye on supporting the agency’s internal IT ...

Korro Bio is laying off a fifth of its workforce as the Novo Nordisk-partnered biotech funnels resources to its ...

RallyBio is steering around more tight corners as it announces a further 40% reduction in staffers just weeks after ...

GSK has shared the data behind its phase 3 liver disease win, revealing patients on linerixibat reported reductions in ...

Takeda has shot down candidates acquired in its $525 million Maverick Therapeutics takeover, blowing a hole in its oncology R ...

California investment firm Vivo Capital has secured $740 million in commitments to be aimed at preclinical- and ...

Charles River CEO James Foster had previously attributed the 2024 revenue dip to decreased demand from biopharma clients. In ...

CRISPR Therapeutics has reported reductions in triglycerides and LDL cholesterol of more than 80% after a single dose of its ...

GE HealthCare has obtained the FDA’s blessing for its latest imaging system combining SPECT and CT scanning, as well as for ...

Roche is rolling out a new diagnostic test to help assess hidden liver fibrosis in patients showing signs of metabolic ...